Ascendis Pharma AS annual free cash flow for fiscal 2025 was €44 million, compared with -€308 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | — | €44M | (€308M) | (€470M) | (€510M) | (€442M) | (€293M) | (€181M) | (€141M) | (€96M) | (€61M) | (€45M) | (€19M) | €5M | (€1M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | — | (€16M) | €67M | €2M | (€12M) | (€15M) | (€88M) | (€57M) | (€62M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ASND metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All ASND financial statements → Interactive ASND charts →
About TickerBase · Data methodology & sources · Privacy · Terms